Lipoprotein(a)-Lowering Medication Agent to Reduce Cardiovascular Events

Дата публикации: 25-09-2026 00:00:00

The experimental drug pelacarsen did not reduce the risk of adverse cardiovascular events in a phase 3 study, despite lowering lipoprotein(a) (Lp[a]) levels, the manufacturer announced.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease	0	3.79	03-09-2026
2	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026
3	GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	0	19.82	07-01-2026
4	Both High and Low Testosterone Tied to Higher Atrial Fibrillation Risk	0	5.5	25-09-2026
5	GLP-1 Drugs Not the Most Effective Treatment for Obstructive Sleep Apnea	0	9.78	25-09-2026
6	Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA	0	6.94	28-04-2026
7	GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026	0	19.07	28-07-2026
8	European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease	0	7.44	26-09-2026
9	Errors in Results, Figure 3, and Supplement 1	0	17.4	24-09-2026
10	GLP-1 drugs may help sleep apnea, but CPAP remains best treatment: Study	0	8.6	27-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.34. Источник: www.jamanetwork.com.